A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)

Trial Profile

A Phase III, Randomised, Open-Label, Comparative Study of Intravenous Iron Isomaltoside 1000 (Monofer®) and Iron Sucrose in Subjects With Iron Deficiency Anaemia and Who Are Intolerant or Unresponsive to Oral Iron Therapy or Who Need Iron Rapidly (PROVIDE)

Completed
Phase of Trial: Phase III

Latest Information Update: 14 Mar 2017

At a glance

  • Drugs Iron isomaltoside 1000 (Primary) ; Iron sucrose
  • Indications Iron deficiency anaemia
  • Focus Registrational; Therapeutic Use
  • Acronyms PROVIDE
  • Sponsors Pharmacosmos
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 14 Mar 2017 New data from this trial published in the American Journal of Hematology, as reported in a Pharmacosmos Media Release.
    • 14 Mar 2017 Results published in the Pharmacosmos Media Release
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top